成都苑东生物制药股份有限公司 2024 年限制性股票激励计划预留授予激励对象名单 （截至授予日） | 类别 | 获授的限制 | 占本次激励 | 占预留授予时 | | --- | --- | --- | --- | | | 性股票数量 | 计划授予总 | 公司总股本的 | | | （万股） | 量的比例 | 比例 | | 中层管理人员及骨干员工（32 人） | 22.60 | 16.91% | 0.13% | | 本次预留授予限制性股票数量合计 | 22.60 | 16.91% | 0.13% | 一、2024 年限制性股票激励计划预留授予限制性股票分配情况表 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司股 本总额的 1.00%。 2、本次激励计划预留授予激励对象不包括单独或合计持有公司 5%以上股份的股东或实际控制人及其 配偶、父母、子女，不包括公司独立董事、监事。 成都苑东生物制药股份有限公司董事会 2025 年 4 月 28 日 ...

深圳价值在线咨询顾问有限公司 关于 成都苑东生物制药股份有限公司 2024 年限制性股票激励计划 预留授予相关事项 之 独立财务顾问报告 二〇二五年四月 | | | 深圳价值在线咨询顾问有限公司 独立财务顾问报告 第一章 释 义 在本报告中，如无特殊说明，下列简称具有如下含义： | 释义项 | | 释义内容 | | --- | --- | --- | | 苑东生物、本公司、公司 | 指 | 成都苑东生物制药股份有限公司 | | 限制性股票激励计划、本次激 | 指 | 成都苑东生物制药股份有限公司2024年限制性股票 | | 励计划 | | 激励计划 | | 《激励计划（草案）》 | 指 | 《成都苑东生物制药股份有限公司2024年限制性股 | | | | 票激励计划（草案）》 | | | | 《深圳价值在线咨询顾问有限公司关于成都苑东生 | | 本报告、本独立财务顾问报告 | 指 | 物制药股份有限公司2024年限制性股票激励计划预 | | | | 留授予相关事项之独立财务顾问报告》 | | 独立财务顾问、价值在线 | 指 | 深圳价值在线咨询顾问有限公司 | | 限制性股票、第二类限制性股 | 指 | 符合 ...

音德律师事 植德(证)字[2024]014-3 号 二〇二五年四月 北京植德律师事务所 Merits&Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层邮编： 100007 12th Floor, Raffles City Beijing Office Tower,No.1 Dongzhimen SouthStreet, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于成都苑东生物制药股份有限公司 北京植德律师事务所 2024 年限制性股票激励计划调整及 关于成都苑东生物制药股份有限公司 预留部分授予事项的 法律意见书 植德(证)字[2024]014-3 号 致:成都苑东生物制药股份有限公司 北京植德律师事务所（以下称"本所"）接受成都苑东生物制药股份有限公 司(以下称"苑东生物"或"公司")的委托,作为其2024年限制性股票激励计 划(以下称"本次激励计划"或"本激励计划")的专项法 ...

（一）审议通过《关于调整 2024 年限制性股票激励计划授予价格及授予数 量的议案》 本议案已经公司第四届董事会薪酬与考核委员会审议通过。 证券代码：688513 证券简称：苑东生物 公告编号：2025-022 成都苑东生物制药股份有限公司 第四届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第三次会议 于 2025 年 4 月 28 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 4 月 25 日以专人送达、电话通知、电子邮件等形式送达全体董事。本次会议由董 事长王颖女士主持，应出席董事 9 名，实际出席董事 9 名。本次会议的召集、召 开和表决程序符合《中华人民共和国公司法》等相关法规和《成都苑东生物制药 股份有限公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： 根据《成都苑东生物制药股份有限公司 2024 年限制性股票激励计划（草案）》 ...

科创板融资余额较前一交易日减少5.98亿元，融券余额减少1346.41万元。257股融资余额环比增加，113 股融券余额环比增加。 证券时报·数据宝统计显示，截至4月25日，科创板两融余额合计1494.53亿元，较上一交易日减少6.11亿 元。其中，融资余额合计1489.29亿元，较上一交易日减少5.98亿元；融券余额合计5.24亿元，较上一交 易日减少1346.41万元。 融资余额方面，截至4月25日，融资余额最高的科创板股是中芯国际，最新融资余额72.47亿元，其次是 寒武纪、海光信息，融资余额分别为54.67亿元、33.76亿元。环比变动来看，257只科创板个股融资余额 环比增加，环比下降的有327只。融资余额增幅较大的是苑东生物、美埃科技、路维光电，环比上个交 易日增加38.59%、21.10%、18.18%；降幅居前的有康鹏科技、迪哲医药、仕佳光子，环比下降 18.28%、17.20%、16.49%。 融券余额来看，融券余额最高的科创板股是中芯国际，最新融券余额0.25亿元，其次是海光信息、寒武 纪，融券余额分别为0.22亿元、0.18亿元。环比变动来看，113只科创板个股融券余额环比增加，环比下 ...

Core Viewpoint - The report highlights that Yuandong Biopharmaceutical has received approval for new products, which are expected to drive growth through internationalization and innovation, maintaining a "buy" rating for the company [1] Financial Performance - In 2024, the company achieved revenue of 1.35 billion yuan (+20.82% year-on-year), with a net profit attributable to shareholders of 238 million yuan (+5.15%) and a net profit excluding non-recurring items of 175 million yuan (+10.90%). After excluding stock incentive expenses, the net profit increased by 13.47% year-on-year, and the net profit excluding non-recurring items rose by 22.87% [1] - For Q1 2025, the company reported revenue of 306 million yuan (-2.97%) and a net profit attributable to shareholders of 61 million yuan (-19.22%), with a net profit excluding non-recurring items of 46 million yuan (-10.79%). The profit in Q1 2025 was under pressure due to stock incentive expenses [1] Business Segments Growth - The chemical preparations segment generated revenue of 1.077 billion yuan (+22.25%), the raw materials segment 121 million yuan (+28.65%), and the CMO/CDMO business 65 million yuan (+111.59%). However, technical services and transfers saw a decline in revenue of 63 million yuan (-42.81%) [2] - Domestic revenue reached 1.324 billion yuan (+20.04%), while overseas revenue was 25 million yuan (+84.66%). The growth in the chemical preparations segment was driven by both existing and newly approved products, with 13 high-end preparation products approved in 2024 [2] R&D and Innovation - The company invested approximately 290 million yuan in R&D in 2024, accounting for 21.31% of revenue, with 83 million yuan allocated to new drug development [3] - The company has a rich pipeline of products under development, including a diabetes drug that has reached Phase III clinical trials and several other innovative drugs that have received clinical trial approvals [3] Profit Forecast and Investment Rating - The profit forecast for 2025-2026 has been adjusted to 281 million yuan and 335 million yuan, respectively, with an expected profit of 401 million yuan in 2027. The corresponding PE ratios are 21, 18, and 15 times, indicating strong growth potential as new products are approved [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has received approval for new products, which are expected to gradually increase in volume, driving growth through internationalization and innovation [1] - In 2024, the company achieved a total revenue of 1.35 billion yuan, representing a year-on-year increase of 20.82%, and a net profit attributable to shareholders of 238.23 million yuan, up 5.15% year-on-year [7] - The company is focusing on the anesthesia and analgesia sector, with significant investments in research and development, which accounted for 21.31% of revenue in 2024 [7] Financial Performance Summary - Total revenue projections for the company are as follows: 1.35 billion yuan in 2024, 1.59 billion yuan in 2025, 1.90 billion yuan in 2026, and 2.26 billion yuan in 2027, with respective year-on-year growth rates of 20.82%, 18.02%, 18.98%, and 19.31% [1][8] - The net profit attributable to shareholders is projected to be 238.23 million yuan in 2024, 281.30 million yuan in 2025, 335.30 million yuan in 2026, and 400.75 million yuan in 2027, with year-on-year growth rates of 5.15%, 18.08%, 19.20%, and 19.52% respectively [1][8] - The company’s earnings per share (EPS) are expected to be 1.35 yuan in 2024, 1.59 yuan in 2025, 1.90 yuan in 2026, and 2.27 yuan in 2027 [1][8] Business Segment Performance - The chemical formulation segment generated revenue of 1.077 billion yuan in 2024, up 22.25% year-on-year, while the raw materials segment saw revenue of 121 million yuan, an increase of 28.65% [7] - The CMO/CDMO business experienced significant growth, with revenue reaching 65 million yuan, a remarkable increase of 111.59% [7] - The company has successfully launched 16 anesthesia and analgesia products and has over 20 products in development, indicating a strong competitive position in the market [7]

Core Viewpoint - Since the "14th Five-Year Plan," China's pharmaceutical industry has transitioned from a phase of rapid growth to a new stage of high-quality development, shifting from scale expansion to a coordinated improvement of scale and quality [1] Company Performance - In 2024, the company achieved a revenue of approximately 1.35 billion yuan, a year-on-year increase of 20.82%, and a net profit attributable to shareholders of 238 million yuan, up 5.15% year-on-year [2] - Excluding the impact of stock incentive expenses, the net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses increased by 13.47% and 22.87% respectively [2] - The company's revenue from the formulation segment reached 1.077 billion yuan, a growth of 22.25%, while the raw material drug segment generated 121 million yuan, up 28.65% [2] Product Development - The company submitted 18 new formulation product registration applications in 2024 and obtained approvals for 13 new formulation products, including domestic first generics [3] - The company has a strong iterative capability in high-end generics, which continues to contribute to performance growth [3] - The company has completed the industrialization of six special narcotic products and has 16 products listed in the narcotic analgesic field, with over 20 products under research [3][4] R&D Investment - The company maintains a high R&D investment intensity, with 2024 R&D expenditure of approximately 290 million yuan, a year-on-year increase of 16.88%, accounting for 21.31% of revenue [4] - Since 2021, the proportion of R&D investment to revenue has consistently exceeded 20% [4] Internationalization Strategy - The company has made significant progress in internationalizing its raw materials, with several products receiving international approvals, including FDA and EU certifications [7] - The company has successfully commercialized its first product in the U.S. market, marking a breakthrough from 0 to 1 [7] Digital Transformation - In 2024, the company focused on a "digital intelligence" strategy, enhancing its industrial platform and achieving digital management across the entire drug research and production process [8] - The company has received certifications for data management and intelligent manufacturing capabilities, indicating progress in its digital transformation efforts [8] Future Outlook - In 2025, the company aims to accelerate its transformation from generics to innovation, positioning innovation as the core engine for high-quality development [8]

Core Insights - Chengdu Yuandong Pharmaceutical Co., Ltd. reported a record high revenue of 1.35 billion RMB in 2024, marking a year-on-year growth of 20.82% [1] - The net profit attributable to shareholders reached 238 million RMB, with a growth of 5.15%, and a net profit growth of 13.47% after excluding stock incentive expenses [1] - The company plans to distribute a cash dividend of 4.3 RMB per 10 shares to all shareholders [1] Revenue Breakdown - The formulation segment generated 1.077 billion RMB, reflecting a year-on-year increase of 22.25% [1] - The raw material segment achieved 121 million RMB in revenue, up 28.65% year-on-year [1] - CMO/CDMO business saw a significant revenue increase of 111.59%, reaching 65.2 million RMB [1] Product Development and Approvals - Yuandong submitted 18 new formulation product registration applications and received approvals for 13 products, including domestic first generics [2] - The company is advancing its international strategy, with key approvals from the FDA and EU for various raw materials [2] - The company successfully shipped its first product to the U.S. market, marking a significant commercial breakthrough [2] Digitalization and R&D Investment - The company is accelerating the integration of digitalization and smart manufacturing in the pharmaceutical industry [3] - R&D investment reached approximately 288 million RMB, a year-on-year increase of 16.88%, with nearly 30% allocated to new drug development [3] - Over 10 first-class new drugs are currently in the research pipeline [3] Strategic Focus and Market Position - The company maintains a strong focus on the anesthetic and analgesic sector, establishing a comprehensive industry chain from raw materials to formulations [4] - The integration of R&D systems with international standards supports the company's new drug development and market expansion [4] - The company's ability to innovate and respond quickly to market changes enhances its competitive edge in a challenging market environment [3][4]

（二）公司《第四届监事会第二次会议决议公告》。 五、监事会意见 监事会认为：公司本次进行现金管理的资金来源为公司闲置自有资金，在符合国家法律法规和保障投资 安全的前提下，进行现金管理有利于提高资金使用效率，能够获得一定的投资收益，不影响公司日常经 营资金需求及公司主营业务的正常开展，符合公司及全体股东的利益，不存在损害公司及全体股东，特 别是中小股东利益的情形。同意公司使用闲置自有资金进行现金管理。 六、上网公告附件 （一）公司《第四届董事会第二次会议决议公告》； 登录新浪财经APP 搜索【信披】查看更多考评等级 三、对公司日常经营的影响 公司对闲置自有资金进行现金管理系以有效控制为前提，实施时将确保公司正常运营和资金安全，不影 响公司日常资金正常周转或公司主营业务的发展。公司及下属子公司使用闲置自有资金进行现金管理， 可以提高闲置自有资金的使用效率，增加公司投资收益，为公司及股东获取更多回报。 四、对使用闲置自有资金进行现金管理需履行的审议程序 公司于2025年4月24日召开第四届董事会第二次会议及第四届监事会第二次会议，审议通过了《关于使 用闲置自有资金进行现金管理的议案》，本事项属于公司董事会决策权限范 ...